Comments
Shares of Sun Pharmaceutical Industries surged over 2 per cent after the US Supreme Court ruling on a patent litigation by its subsidiary Caraco Pharmaceutical Laboratories.
In a regulatory filing, Sun Pharma said the US Supreme court has ruled in favour of Caraco in its patent litigation against Novo-Nordisk over Caraco’s generic version of Prandin, Repaglinide tablets.
The company said that it is a landmark judgment for generic companies.
Reacting to the development, the shares of the company witnessed a record high of Rs 599 on the BSE, a jump of 2.53 per cent over its last closing price of Rs 584.20. The scrip was later trading at Rs 596.90, up 2.17 per cent.
A similar movement was witnessed on the National Stock Exchange as well, where the stock opened at Rs 588.05, then jumped 2.61 per cent to see a high of Rs 600. It was later trading at Rs 597.15, up 2.13 per cent.
Marketmen said the positive news helped the stock gain momentum. Besides, the broader market was also trading in the positive territory.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.